Jim Cramer's Stop Trading: GWPH

NEW YORK (TheStreet) -- Morgan Stanley initiated coverage on GW Pharma (GWPH) with a buy rating and a $103 price target.

"This stock will be up the most of any stock other than Allergan (AGN) today," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment. 

"This is a cannabis stock" -- not a medical marijuana stock, he argued. He said GW Pharma is "a real company" that has other business segments, while also having operations in the medical marijuana field.  

"I am shocked at this" bold and timely analyst action, Cramer concluded, calling GW Pharma his favorite cannabis stock.


-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Trump Blinks on China Trade War That's Looking Harder to Win

Trump Blinks on China Trade War That's Looking Harder to Win

Monday Madness: GE, China, and Micron

Monday Madness: GE, China, and Micron

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

How Technology Will Unleash the Legal Marijuana Industry's Growth Potential

How Technology Will Unleash the Legal Marijuana Industry's Growth Potential

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense